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Abstract
Management of venous thromboembolism (VTE) in patients in advanced cancer can be difficult due to the
increased risk of recurrent and extending VTE despite therapeutic anticoagulation, and of bleeding due to or
exacerbated by anticoagulation. Currently, best practice is long term administration of low molecular weight
heparin (LMWH), but a recurrent VTE and bleeding rate remains, and some patients have contra-indications
to anticoagulation. Newer anticoagulants such as oral anti-thrombin agents and biotinylated idrapurinux
may have a role in the future.
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Introduction
Cancer patients have an increased risk of VTE
compared with patients without cancer due to the
secretion of cancer-related procoagulants, which
increase with advancing disease [1–5]. Up to 15%
of cancer patients are estimated to develop clinical-
ly apparent VTE, although this is likely to be an
underestimate of the problem [1, 4). The preva-
lence of both symptomatic and undiagnosed VTE in
advanced disease is thought to be as high as 52%,
which is in keeping with post-mortem studies [6–
8]. Recent work with patients with advanced cancer
of the pancreas — one of the most thrombogenic
tumours — highlights the problem of “early death
burden” in clinical trials, that is, death within 12
weeks, which affects nearly a quarter of participants
[9]. The pilot work with chemo-anticoagulation in
this highly thrombogenic cancer suggests that up
to 75% of early death burden in pancreatic cancer
patients could be due to hitherto unrecognised and
unreported VTE. The coexistence of VTE with cancer
has been shown in a number of studies to have
significant negative impact on survival [10, 11].
Most of these data however pertain to the rela-
tively fit ambulant patients with cancer. The data
for the poor performance status patients (ECOG >
2 or Karnofsky < 60) which form the bulk of the
conventional “palliative” caseload are much less ro-
bust. This review aims to summarise these and offer
some insight into best practice and avenues of much
needed further research.
Concerns regarding patients
with advanced cancer
Management of patients with VTE and cancer,
especially those with advanced disease, can be
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fraught with difficulty as there is an increased risk
of both bleeding with, and further episodes of VTE
despite, anticoagulation, particularly with warfarin
compared with non-cancer patients [12–24]. The
risk becomes greater with progressive cancer [24]
and thus clinical decision-making may not be easy
in patients for whom the focus of treatment is pal-
liative, but who are not imminently dying. The risk
worsens with advanced disease not only because of
increased risk of ulcerating lesions or tumour mass-
es compressing venous return, but because of wors-
ening disseminated intravascular coagulation (DIC)
which results in increasing activation of the coagu-
lation cascade and a tendency to bleed. In addition,
thrombocytopenia, due to marrow invasion or as a
complication of treatment, increases the risk of
bleeding. This is also the patient group for whom
even a relatively minor insult such as a small pulmo-
nary embolus (PE) or minor deep vein thrombosis
(DVT) may have a disproportionately large impact
on quality of life at a time when time itself is pre-
cious.
Current guidance
Warfarin is less effective and may carry a high-
er risk of bleeding than LMWH in patients with
advanced cancer. Four randomised controlled
studies comparing warfarin and long-term low
molecular weight heparin (LMWH) treatment in-
dicate that LMWH is more effective at preventing
recurrent VTE in cancer patients [15, 18, 20, 21].
One of these studies also showed LMWH to be
safer in terms of bleeding complications [15]. It is
difficult to judge the number of patients with
advanced disease included in these studies, in-
deed, two excluded patients with poor perfor-
mance status (ECOG 3 and 4) [18, 20]. However,
over 40% of patients in each study were classed
as having metastatic disease or were no longer
receiving active treatments for their cancer. These
studies did not show worse bleeding with war-
farin. It is therefore hard to apply these results to
a population with advanced cancer where clini-
cians may be so concerned about the risks of treat-
ment that they are reluctant to treat at all, or to
treat at a reduced dose in an attempt to minimise
risk [25]. A recent systematic review and meta-
analysis has attempted to apply this evidence base
to patients with advanced disease [26], and a more
in depth discussion of the particular issues facing
patients with advanced disease and VTE is also
available [27].
Application to advanced disease
A prospective cohort study of cancer patients
with VTE treated with warfarin showed a clear in-
creased risk of recurrent thrombosis with advanced
disease; extensive disease — hazard ratio; 4.6, mod-
erately extensive — hazard ratio; 5.3 and less exten-
sive disease — hazard ratio; 1.9. For bleeding, the
differential hazard ratios were: 4.8 for extensive dis-
ease, 2.5 for moderately extensive and 0.5 for less
extensive [24]. Other prospective cohort and retro-
spective studies have shown a high risk of bleeding
in cancer patients anticoagulated with warfarin. Thus
treating with long-term LMWH seems to be the most
effective and safe approach in patients with ad-
vanced disease for whom anticoagulation is deemed
to be appropriate.
Monreal et al. published the results of a pro-
spective cohort of 203 cancer patients with dissem-
inated disease and VTE treated with a modified dose
long-term LMWH regime [28]. This patient group
therefore, does seem to match more closely the pop-
ulation of concern.  In an attempt to reduce the risk
of anticoagulant related bleeding, patients were
treated with full weight adjusted treatment dose of
Dalteparin for 7 days, and the dose reduced to
10,000 u daily thereafter. There was further dose
reduction if the patient had thrombocytopenia.
Major bleeding occurred in 5.4% which compares
with 6–7% [20, 21] on full dose LMWH. 8.9% had
recurrent VTE which compares with 2.8–8% [20,
21] on full dose LMWH.
Occasionally, patients with advanced disease may
need to be considered for unfractionated heparin
(UFH) therapy. This is usually in specific circumstanc-
es e.g. peri-operatively in a patient with cancer and
VTE, in whom the risk of recurrent/progressive VTE
is too high to risk stopping the LMWH for very long,
and the flexibility of UFH's short half life and ability
to completely reverse with protamine sulfate is use-
ful. Another indication for UFH would be for pa-
tients with renal failure on haemodialysis. Occasion-
ally, a cancer patient will have VTE resistant to LMWH
because of tumour driven direct thrombin activa-
tion which will bypass the factor Xa inhibiting ac-
tivity of LMWH. It is hoped that the new oral throm-
bin inhibitors would have a role to play in the future
and this is discussed later in this article. However, it
is unclear yet whether the theoretical benefit of di-
rect thrombin inhibition will bring with it an in-
creased risk of bleeding.
There is little published work specifically looking
at patients with advanced cancer and no randomised
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controlled trials. A survey of UK palliative physicians
showed that only 20% thought that they would an-
ticoagulate hospice out-patients with VTE, and only
6% would anticoagulate hospice in-patients [25].
Specific concerns raised were problems of drug in-
teractions, INR control and bleeding with warfarin.
Some would opt for using very low dose warfarin
(1mg per day) thus providing less effective second-
ary VTE prevention and a continued risk of bleeding.
The survey was carried out in the 1990s and is there-
fore now out of date, but even then there was a
move to use LMWH in these patients in preference to
warfarin, if anticoagulation was to be considered.
Interestingly, for a single postal questionnaire sur-
vey, there was a high response rate (75%) indicating
that this was considered an important area.
What about the patient
who is bleeding?
There is no published evidence to guide the clini-
cian in this particularly challenging situation and
management should be tailored to the individual
after full discussion of the risks of each treatment
option [27]. A sensible first step is to try and stop
the bleeding if possible. If this is not possible, then
mild, nuisance bleeding such as mild epistaxis or
haemoptysis should not prevent anticoagulation in
patients with symptomatic proximal DVT or PE in-
volving segmental or more central pulmonary arter-
ies in whom the risk of clinically significant PE is
high. If the bleeding is from a visible, easily moni-
tored and unlikely life-threatening source then full
anticoagulation should commence (or be continued)
but be followed up carefully. If the bleeding is due
to mucosal involvement by tumour, such as bowel,
duodenal, bladder or vaginal disease a more cau-
tious approach of reduced or even prophylactic doses
should be used and the patient monitored closely.
The haemostatic properties of a palliative course
(usually a single or a couple of fractions) of radia-
tion should not be forgotten as it tends not to be
too onerous for the poor performance patient and
rarely adds to the morbidity [29]. If haemoglobin
remains stable and bleeding does not worsen, the
dose can be slowly titrated up. A twice daily LMWH
regime, rather than once daily, may smooth out
peaks and troughs in anticoagulation level. If there
is active bleeding of a more serious and potentially
life threatening nature (intracranial, retroperitoneal
or upper gastrointestinal bleeding), then anticoag-
ulation is contraindicated. A vena caval filter may
be considered for patients with proximal DVT.
Vena caval interruption
There is no evidence that insertion of a vena
caval filter improves outcome for cancer patients
with VTE who are bleeding and published studies
are too small for useful conclusions [30–35]. How-
ever, for patients with contraindications to antico-
agulation, or who continue to embolise despite ther-
apeutic anticoagulation, there is little other option
and individual patients may gain some benefit. Fil-
ter insertion does not suppress the underlying hy-
percoagulable state, and there is concern that its
presence may even stimulate clot extension. In ad-
dition, fatal PE can still result from thrombus for-
mation in the vena cava proximal to the filter, and
this complication has been reported in cancer pa-
tients. Filters can be permanent, or if only a tempo-
rary cessation of anticoagulant therapy is needed,
e.g. peri-operatively, retrievable ones may be used.
What about primary
thromboprophylaxis?
Noble et al. [36] has published a telephone sur-
vey of palliative physician opinion and practice re-
garding VTE primary prophylaxis. They compared
opinion and practice from 2000 (74% response) and
2005 (91% response). Over this time practice
changed from 62% physicians in 2000 routinely stop-
ping VTE prophylaxis even in high risk good prog-
nosis patients, to only 18% in 2005. The authors
suggest that there is a growing awareness of the
problem of VTE in patients with advanced cancer
amongst palliative physicians and a growing per-
ception that LMWH is an acceptable form of antico-
agulation — at least for primary prophylaxis [37].
What happens if the patient
is not anticoagulated?
Untreated, the risk of further VTE, either exten-
sion or recurrence, is thought to be high, although
hard to ascertain from the literature, and may range
from no symptoms, to debilitating symptoms, to
early death from catastrophic cardiovascular col-
lapse. Post mortem studies show that 50% of prox-
imal DVTs embolise to the lungs [38] but it is less
easy to ascertain which of these are of clinical sig-
nificance. VTE is a great mimic clinically and further
post-mortem evidence suggests that it is poorly rec-
ognised; treated as pneumonia or myocardial inf-
arction [38]. Havig [38] also showed that 25% of
patients took over an hour to die, with two-thirds
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of the abruptly dead having symptoms of “adver-
tising emboli”; thus even fatal PE may be the cause
of considerable morbidity that is potentially pre-
ventable or treatable.
Obtaining data in patients that have had a VTE
and who have not been anticoagulated is difficult.
The closest we can come to obtaining reasonable
figures is to study  patients with DVT who have had
a vena caval filter inserted because of an absolute
contraindication to systemic anticoagulation [39–
43].  Such data suggests a thrombosis rate of 7–
10% per month (of which approximately half will
be symptomatic) during the first 3 months follow-
ing insertion of a device. Further data can be ob-
tained from the more modern retrievable filters that
once again tend to be used without anticoagulants
and are removed fairly quickly (usually recommend-
ed to be taken out before 3 months) [44, 45].
Clinicians may consider that for advanced can-
cer patients, a fatal PE is a “quick and easy” or
“nice” way to go [46]. However, as described above,
the evidence suggests that this is not necessarily so.
As clinical decision making moves further away from
the traditional paternalistic model to a patient-cen-
tred one, we need to understand, not only the RCT
evidence based for management options, but also
how the patient feels about them, and what risks
are acceptable to them. We know from previous
work in lung cancer patients, that a significant group
would be prepared to accept a much higher risk
from chemotherapy treatment for a smaller gain,
than their clinicians [47].
We are also aware that cancer patients value
being included in decisions regarding VTE primary
prophylaxis, feeling that they were still being con-
sidered for the best treatment and not being “given
up on” [37].
The unpredictable nature of recurrent VTE may
also be a problem for a group of patients for whom
“last goals” are important, such as family events
and a relatively sudden, but unpleasant death can
contribute to family distress in bereavement. In a
recent study, Noble et al. demonstrated that pa-
tients wish to be included in treatment decisions
and not treated with clinical paternalism with this
regard, at least with VTE prophylaxis [37].
Future therapeutic options
and indications
The release of new oral Xa inhibitors (e.g. Rivar-
oxaban) and direct thrombin inhibitors (e.g. Dabig-
atran, Apixaban) are a potentially exciting develop-
ment in the prevention and treatment of VTE in the
palliative care setting. Currently they are only li-
censed in the primary thromboprophylaxis of elec-
tive hip and knee surgery but are being evaluated
for a breadth of primary and secondary thrombo-
prophylaxis indications. If demonstrated to be as
efficacious and safe as the LMWHs they will have a
profound impact on the management of palliative
care patients with respect to quality of life and health
resource usage.
Other attractive options include idrapurinux
which is a synthetic pentasaccharide with a very
high affinity for antithrombin. It has a long half life
which enables a once weekly injection which may
be an attractive alternative for palliative care pa-
tients. However, concerns about major bleeding, of
especial concern given its long half life, have limited
its acceptance in patients with advanced disease.
Recently, though, a biotinylated form of idrapurinux
has been introduced into clinical trials which allow
neutralisation of anticoagulant effect using avidin,
providing a potentially useful way round this prob-
lem.
Anticancer effects of anticoagulants
There is small but developing research evidence
of possible direct antineoplastic effects of antico-
agulants. In vitro studies have shown that warfarin,
heparin, fibrinolytics, and even antiplatelet agents
inhibit tumor growth and metastasis [48]. Throm-
bin and fibrin have been found to contribute to the
adhesion and implantation of tumor cells, so antifi-
brin or antithrombin agents might exert their ef-
fects by inhibiting this implantation. Furthermore,
heparin has been found to inhibit vascular endot-
helial growth factor, tissue factor, and platelet-acti-
vating factor, each of which may contribute to an-
giogenesis. It has also been hypothesized that fi-
brin deposits around tumors may offer protection
against immune surveillance, so that anticoagulants
might aid in immune clearance of small deposits of
cancer cells. More recently a major anti-neoplastic,
anti-metastatic effect of the heparins has been
shown to be mediated through anti P and E- selec-
tin properties [49].
Although this is an exciting area, in the recent
meeting at the American Society of Hematology
(2008), major opinion leaders in the field (Zachars-
ki, Varki) expressed the view that the effect of these
agents is more likely to be relevant in the earlier
stages of cancer (e.g adjuvant setting) or in the very
fit population of cancer patients with small volume
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disease that may have time for the impact of pro-
tection against further increase in tumour burden
to have a practical, measurable impact on survival.
It is for these reasons that the likelihood that the
more end-stage spectrum of cancer patients seen
with advanced disease may not be those who will
experience significant improvement from direct an-
tineoplastic effects of these agents as developed at
present. Potentially however, combinations of non-
toxic agents that can deliver tumour stasis through
inhibition of complex mechanisms including those
of the anticoagulation pathways without the need
for concurrent aggressive anticancer treatment may
benefit even the patients with advanced cancer in
the future.
Future challenges
The holistic, individualised nature of palliative
care makes it difficult to develop blanket guidelines
that are applicable to a heterogeneous population
covering a breadth of histology, stage, performance
status and prognosis. Clearly not all palliative care
patients will benefit from prophylaxis or treatment
of an established VTE and the challenge remains for
us to identify those that are likely to benefit with-
out burdening those who will not.
Robust, properly powered studies with appro-
priate outcome measures are required, but the chal-
lenges of conducting such clinical trials in the pal-
liative setting cannot be underestimated.  To an-
swer such questions will require wide collaboration
from many clinical units if sufficient numbers are to
be recruited to future palliative care VTE studies.
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